S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
NASDAQ:ALGN

Align Technology Competitors

$563.21
-1.90 (-0.34 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$558.00
Now: $563.21
$576.35
50-Day Range
$509.64
MA: $571.66
$620.45
52-Week Range
$127.88
Now: $563.21
$634.46
Volume916,630 shs
Average Volume596,188 shs
Market Capitalization$44.41 billion
P/E Ratio25.62
Dividend YieldN/A
Beta1.68

Competitors

Align Technology (NASDAQ:ALGN) Vs. WST, COO, XRAY, QDEL, HAE, and STAA

Should you be buying ALGN stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Align Technology, including West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), and STAAR Surgical (STAA).

West Pharmaceutical Services (NYSE:WST) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares West Pharmaceutical Services and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Align Technology76.00%68.99%46.64%

Earnings & Valuation

This table compares West Pharmaceutical Services and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion11.20$241.70 million$3.2485.83
Align Technology$2.41 billion18.45$442.78 million$4.96113.55

Align Technology has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for West Pharmaceutical Services and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Align Technology14902.57

West Pharmaceutical Services presently has a consensus price target of $310.00, indicating a potential upside of 11.47%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than Align Technology.

Summary

Align Technology beats West Pharmaceutical Services on 9 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares The Cooper Companies and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Align Technology76.00%68.99%46.64%

Earnings & Valuation

This table compares The Cooper Companies and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.84$238.40 million$9.6440.24
Align Technology$2.41 billion18.45$442.78 million$4.96113.55

Align Technology has lower revenue, but higher earnings than The Cooper Companies. The Cooper Companies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

The Cooper Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for The Cooper Companies and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04702.64
Align Technology14902.57

The Cooper Companies presently has a consensus price target of $360.0769, indicating a potential downside of 7.18%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given The Cooper Companies' stronger consensus rating and higher probable upside, equities research analysts plainly believe The Cooper Companies is more favorable than Align Technology.

DENTSPLY SIRONA (NASDAQ:XRAY) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares DENTSPLY SIRONA and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
Align Technology76.00%68.99%46.64%

Earnings & Valuation

This table compares DENTSPLY SIRONA and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.21$262.90 million$2.4524.19
Align Technology$2.41 billion18.45$442.78 million$4.96113.55

Align Technology has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

DENTSPLY SIRONA has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for DENTSPLY SIRONA and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA16802.47
Align Technology14902.57

DENTSPLY SIRONA presently has a consensus price target of $55.00, indicating a potential downside of 7.20%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given DENTSPLY SIRONA's higher probable upside, equities research analysts plainly believe DENTSPLY SIRONA is more favorable than Align Technology.

Summary

Align Technology beats DENTSPLY SIRONA on 11 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Quidel and Align Technology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel11302.40
Align Technology14902.57

Quidel presently has a consensus price target of $245.60, indicating a potential upside of 52.27%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given Quidel's higher probable upside, equities research analysts plainly believe Quidel is more favorable than Align Technology.

Insider and Institutional Ownership

84.0% of Quidel shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Quidel and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million12.76$72.92 million$2.7359.08
Align Technology$2.41 billion18.45$442.78 million$4.96113.55

Align Technology has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quidel and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
Align Technology76.00%68.99%46.64%

Volatility & Risk

Quidel has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Summary

Align Technology beats Quidel on 12 of the 14 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Insider & Institutional Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Align Technology and Haemonetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion18.45$442.78 million$4.96113.55
Haemonetics$988.48 million6.44$76.53 million$3.3137.84

Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Align Technology and Haemonetics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology14902.57
Haemonetics00503.00

Align Technology currently has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 15.62%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Align Technology.

Profitability

This table compares Align Technology and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Haemonetics11.76%22.85%10.40%

Risk and Volatility

Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Summary

Align Technology beats Haemonetics on 9 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Earnings and Valuation

This table compares STAAR Surgical and Align Technology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million32.17$14.05 million$0.46225.54
Align Technology$2.41 billion18.45$442.78 million$4.96113.55

Align Technology has higher revenue and earnings than STAAR Surgical. Align Technology is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by insiders. Comparatively, 1.2% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares STAAR Surgical and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
Align Technology76.00%68.99%46.64%

Analyst Ratings

This is a breakdown of recent ratings and target prices for STAAR Surgical and Align Technology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
Align Technology14902.57

STAAR Surgical presently has a consensus target price of $68.50, indicating a potential downside of 33.98%. Align Technology has a consensus target price of $475.4615, indicating a potential downside of 15.58%. Given Align Technology's stronger consensus rating and higher possible upside, analysts plainly believe Align Technology is more favorable than STAAR Surgical.

Volatility & Risk

STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Align Technology beats STAAR Surgical on 11 of the 14 factors compared between the two stocks.


Align Technology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
2.1$278.10-1.8%$20.61 billion$1.84 billion73.38Dividend Announcement
Decrease in Short Interest
The Cooper Companies logo
COO
The Cooper Companies
1.7$387.92-0.8%$19.06 billion$2.43 billion80.65Upcoming Earnings
Analyst Report
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$59.27-0.7%$12.95 billion$4.03 billion-257.70Earnings Announcement
Dividend Announcement
Analyst Report
News Coverage
Quidel logo
QDEL
Quidel
2.4$161.29-3.4%$6.83 billion$534.89 million18.93
Haemonetics logo
HAE
Haemonetics
1.6$125.24-3.3%$6.36 billion$988.48 million60.50Increase in Short Interest
Gap Up
STAAR Surgical logo
STAA
STAAR Surgical
1.4$103.75-2.7%$4.83 billion$150.18 million546.08Increase in Short Interest
Analyst Revision
Neogen logo
NEOG
Neogen
1.2$81.51-3.1%$4.34 billion$418.17 million71.50
ICU Medical logo
ICUI
ICU Medical
1.5$204.72-1.3%$4.30 billion$1.27 billion54.16Earnings Announcement
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.7$55.26-0.7%$3.07 billion$994.85 million-104.26Earnings Announcement
Analyst Revision
Atrion logo
ATRI
Atrion
1.1$629.58-1.5%$1.17 billion$155.07 million35.47Dividend Announcement
Cerus logo
CERS
Cerus
1.5$6.46-0.9%$1.09 billion$74.65 million-16.56Earnings Announcement
Unusual Options Activity
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$21.50-2.6%$927.62 million$253.67 million19.91Analyst Report
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$11.08-0.2%$794.80 million$154.60 million-48.17Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.06-10.8%$676.69 million$123.86 million67.68High Trading Volume
News Coverage
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.7$38.20-1.4%$543.01 million$114.51 million-81.28Upcoming Earnings
Utah Medical Products logo
UTMD
Utah Medical Products
1.0$88.00-0.9%$320.32 million$46.90 million27.76
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.